JP2011507972A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011507972A5 JP2011507972A5 JP2010540953A JP2010540953A JP2011507972A5 JP 2011507972 A5 JP2011507972 A5 JP 2011507972A5 JP 2010540953 A JP2010540953 A JP 2010540953A JP 2010540953 A JP2010540953 A JP 2010540953A JP 2011507972 A5 JP2011507972 A5 JP 2011507972A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- virus
- helix
- amino acid
- carbon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 150000001413 amino acids Chemical group 0.000 claims 17
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims 7
- 108010075254 C-Peptide Proteins 0.000 claims 7
- 241000700605 Viruses Species 0.000 claims 7
- 208000036142 Viral infection Diseases 0.000 claims 6
- 230000009385 viral infection Effects 0.000 claims 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 3
- 241000711573 Coronaviridae Species 0.000 claims 2
- 238000010485 C−C bond formation reaction Methods 0.000 claims 2
- 241001115402 Ebolavirus Species 0.000 claims 2
- 241000711950 Filoviridae Species 0.000 claims 2
- 241000700586 Herpesviridae Species 0.000 claims 2
- 241000282414 Homo sapiens Species 0.000 claims 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 2
- 241001559185 Mammalian rubulavirus 5 Species 0.000 claims 2
- 241000711466 Murine hepatitis virus Species 0.000 claims 2
- 241000712464 Orthomyxoviridae Species 0.000 claims 2
- 241000711504 Paramyxoviridae Species 0.000 claims 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims 2
- 241000712907 Retroviridae Species 0.000 claims 2
- 241000315672 SARS coronavirus Species 0.000 claims 2
- 241000713311 Simian immunodeficiency virus Species 0.000 claims 2
- 208000000389 T-cell leukemia Diseases 0.000 claims 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 238000005649 metathesis reaction Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 241000713869 Moloney murine leukemia virus Species 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000006664 bond formation reaction Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 108010091748 peptide A Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1811807P | 2007-12-31 | 2007-12-31 | |
| US61/018,118 | 2007-12-31 | ||
| PCT/US2008/088667 WO2009110952A2 (en) | 2007-12-31 | 2008-12-31 | Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011507972A JP2011507972A (ja) | 2011-03-10 |
| JP2011507972A5 true JP2011507972A5 (cg-RX-API-DMAC7.html) | 2012-02-23 |
| JP5653219B2 JP5653219B2 (ja) | 2015-01-14 |
Family
ID=41056505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010540953A Expired - Fee Related JP5653219B2 (ja) | 2007-12-31 | 2008-12-31 | 水素結合サロゲートをベースとする人工ヘリックスによるウイルス宿主膜融合の制御 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8871899B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2247298B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5653219B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2710964A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009110952A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007319193A1 (en) * | 2006-11-15 | 2008-05-22 | Dana-Farber Cancer Institute, Inc. | Stabilized MAML peptides and uses thereof |
| BRPI0720306A2 (pt) | 2006-12-14 | 2014-02-04 | Aileron Therapeutics Inc | Sistemas de macrociclização da bis-sufidrila |
| CA2678941C (en) | 2007-02-23 | 2018-11-27 | Aileron Therapeutics, Inc. | Triazole macrocycle systems |
| KR20160061439A (ko) | 2007-03-28 | 2016-05-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| US8613956B2 (en) * | 2008-06-23 | 2013-12-24 | International Flora Technologies, Ltd. | Cosmetic particles that transform from hard to soft particles comprising hydrogenated long-chain triglyceride oils |
| WO2010034034A1 (en) | 2008-09-22 | 2010-03-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| BRPI0920899A2 (pt) | 2008-11-24 | 2016-04-26 | Aileron Therapeutics Inc | macrociclos peptidomiméticos com propriedades melhoradas |
| BRPI1006139A2 (pt) | 2009-01-14 | 2017-05-30 | Aileron Therapeutics Inc | macrociclos peptidomiméticos |
| US20130072439A1 (en) | 2009-09-22 | 2013-03-21 | Huw M. Nash | Peptidomimetic macrocycles |
| MX355543B (es) | 2010-08-13 | 2018-04-20 | Aileron Therapeutics Inc Star | Macrociclos peptidomiméticos. |
| RU2639523C2 (ru) | 2011-10-18 | 2017-12-21 | Эйлерон Терапьютикс, Инк. | Пептидомиметические макроциклы и их применение |
| WO2013059530A2 (en) * | 2011-10-18 | 2013-04-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| JP6450191B2 (ja) | 2012-02-15 | 2019-01-09 | エイルロン セラピューティクス，インコーポレイテッド | ペプチドミメティック大環状化合物 |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| US9604919B2 (en) | 2012-11-01 | 2017-03-28 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| US20140205681A1 (en) | 2013-01-19 | 2014-07-24 | New York University | HYDROGEN-BOND SURROGATE PEPTIDES AND PEPTIDOMIMETICS FOR p53 REACTIVATION |
| US20150065436A1 (en) * | 2013-09-03 | 2015-03-05 | University Of Southern California | INHIBITING INTERACTION BETWEEN HIF-1ALPHA AND p300/CBP WITH HYDROGEN BOND SURROGATE-BASED HELICES |
| SG11201702223UA (en) | 2014-09-24 | 2017-04-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
| WO2016049355A1 (en) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
| EP3294318A4 (en) | 2015-03-20 | 2019-04-03 | Aileron Therapeutics, Inc. | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF |
| US10059741B2 (en) | 2015-07-01 | 2018-08-28 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| JP2018528217A (ja) | 2015-09-10 | 2018-09-27 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子 |
| CN108822190B (zh) * | 2018-05-23 | 2021-11-09 | 中国人民解放军军事科学院军事医学研究院 | 多肽及其药物组合物和用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5446128A (en) | 1993-06-18 | 1995-08-29 | The Board Of Trustees Of The University Of Illinois | Alpha-helix mimetics and methods relating thereto |
| US5840833A (en) | 1995-10-27 | 1998-11-24 | Molecumetics, Ltd | Alpha-helix mimetics and methods relating thereto |
| US6150088A (en) | 1997-04-17 | 2000-11-21 | Whitehead Institute For Biomedical Research | Core structure of gp41 from the HIV envelope glycoprotein |
| US6818740B1 (en) | 1997-04-17 | 2004-11-16 | Whitehead Institute For Biomedical Research | Inhibitors of HIV membrane fusion |
| US6841657B2 (en) | 1997-04-17 | 2005-01-11 | Whitehead Institute For Biomedical Research | Inhibitors of HIV membrane fusion |
| US6596497B1 (en) | 1999-03-17 | 2003-07-22 | New York Blood Center, Inc. | Screening of antiviral compounds targeted to the HIV-1 gp41 core structure |
| US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
| US20030082525A1 (en) | 1999-12-16 | 2003-05-01 | Whitehead Institute For Biomedical Research | Five-Helix protein |
| US7045552B2 (en) | 2002-09-27 | 2006-05-16 | Trimeris, Inc. | Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy |
| CA2830063C (en) | 2003-11-05 | 2017-10-31 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides and uses thereof |
| CA2564031A1 (en) * | 2004-04-23 | 2005-11-03 | Conjuchem Biotechnologies Inc. | Method for the purification of albumin conjugates |
| WO2005118620A2 (en) | 2004-05-27 | 2005-12-15 | New York University | Methods for preparing internally constraied peptides and peptidomimetics |
| CN1968710B (zh) | 2004-06-01 | 2013-12-25 | 默沙东公司 | HIV gp41融合中间体的稳定的肽模拟物 |
| BRPI0720306A2 (pt) | 2006-12-14 | 2014-02-04 | Aileron Therapeutics Inc | Sistemas de macrociclização da bis-sufidrila |
| US7981998B2 (en) | 2006-12-14 | 2011-07-19 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
| CA2678941C (en) | 2007-02-23 | 2018-11-27 | Aileron Therapeutics, Inc. | Triazole macrocycle systems |
| KR20160061439A (ko) | 2007-03-28 | 2016-05-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| CA2713089C (en) | 2008-01-23 | 2017-11-21 | Dana Farber Cancer Institute | Compositions and methods for the treatment of viral infections |
| WO2010034034A1 (en) | 2008-09-22 | 2010-03-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| BRPI0920899A2 (pt) | 2008-11-24 | 2016-04-26 | Aileron Therapeutics Inc | macrociclos peptidomiméticos com propriedades melhoradas |
| US20110223149A1 (en) | 2009-10-14 | 2011-09-15 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
-
2008
- 2008-12-31 JP JP2010540953A patent/JP5653219B2/ja not_active Expired - Fee Related
- 2008-12-31 US US12/811,088 patent/US8871899B2/en active Active
- 2008-12-31 EP EP08873198.9A patent/EP2247298B1/en not_active Not-in-force
- 2008-12-31 WO PCT/US2008/088667 patent/WO2009110952A2/en not_active Ceased
- 2008-12-31 CA CA2710964A patent/CA2710964A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011507972A5 (cg-RX-API-DMAC7.html) | ||
| Nichols et al. | Respiratory viruses other than influenza virus: impact and therapeutic advances | |
| Root et al. | HIV-1 gp41 as a target for viral entry inhibition | |
| EP4400510A3 (en) | Improved vaccines and methods for using the same | |
| JP2010535495A5 (cg-RX-API-DMAC7.html) | ||
| WO2009110952A3 (en) | Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices | |
| SI2898885T1 (en) | Pyrrolopyrimidine derivatives for use in the treatment of viral infections | |
| NZ602504A (en) | Antiviral vaccines with improved cellular immunogenicity | |
| JP2009537143A5 (cg-RX-API-DMAC7.html) | ||
| RU2014106765A (ru) | Производные витамина в6 нуклеотидов, ациклических нуклеотидов и ациклических нуклеозидных фосфонатов | |
| WO2009094191A3 (en) | Methods of treating viral infections | |
| ZA201001556B (en) | Polyethylene glycol modified interferon alpha 2b and preparation method and applications thereof | |
| JP2011519414A5 (cg-RX-API-DMAC7.html) | ||
| WO2008144584A3 (en) | Cysteic acid derivatives of anti-viral peptides | |
| EA200901412A1 (ru) | Замещенные индолы, способ их получения и применения | |
| WO2007033444A3 (en) | Antiviral therapy with carbohydrate binding agents | |
| WO2008064072A3 (en) | Anti-tsg101 antibodies and their uses for treatment of viral infections | |
| SG170825A1 (en) | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | |
| Murray et al. | A low-molecular-weight entry inhibitor of both CCR5-and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41 | |
| WO2005076001A3 (en) | A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual | |
| Jinno et al. | Inhibition of cell-free human T-cell leukemia virus type 1 infection at a postbinding step by the synthetic peptide derived from an ectodomain of the gp21 transmembrane glycoprotein | |
| Tee et al. | Estimating the date of origin of an HIV-1 circulating recombinant form | |
| Bibollet-Ruche et al. | Complete genome analysis of one of the earliest SIVcpz Ptt strains from Gabon (SIVcpzGAB2) | |
| JP2010511706A5 (cg-RX-API-DMAC7.html) | ||
| EA200601218A1 (ru) | Респираторно-синцитиальный вирус с перекрёстно компенсированным геномным дефицитом |